Najat Khan, Chief R&D Commercial Officer: Recursion Pharmaceuticals RXRX Sell · Filed 25/12/29

Trade details

Type: Insider sale
Amount: $548,617.23
Shares · price: 124,403 sh · $4.41 a share
Held after: 611,135 sh
Stock: Recursion Pharmaceuticals RXRX
Person: Najat KhanChief R&D Commercial Officer
Trade date: 25/12/22
Filed: 25/12/29
Days to filing: 7 days

Sold 16.9% of holdings

Share of holding sold: 16.9%

Recursion Pharmaceuticals trades, last 26 weeks

What else happened in Recursion Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 25/11/22~01/21

Najat Khan's recent trades

Najat KhanCEO and President
Planned sale10b5-1 planRecursion Pharmaceuticals
Planned sale10b5-1 plan
Recursion Pharmaceuticals
RXRX
$78.8K
22,408 sh
$78.8K
Filed 09/08
Traded 09/08
Najat KhanCEO and President
Sell10b5-1 planRecursion Pharmaceuticals
Sell10b5-1 plan
Recursion Pharmaceuticals
RXRX
$84.4K
23,588 sh
$84.4K
Filed 06/05
Traded 06/05
Najat KhanCEO and President
Planned sale10b5-1 planRecursion Pharmaceuticals
Planned sale10b5-1 plan
Recursion Pharmaceuticals
RXRX
$84.5K
23,588 sh
$84.5K
Filed 06/05
Traded 06/05
Najat KhanCEO and President
Sell10b5-1 planRecursion Pharmaceuticals
Sell10b5-1 plan
Recursion Pharmaceuticals
RXRX
$94.8K
28,298 sh
$94.8K
Filed 03/11
Traded 03/09
Najat KhanCEO and President
Planned sale10b5-1 planRecursion Pharmaceuticals
Planned sale10b5-1 plan
Recursion Pharmaceuticals
RXRX
$94.7K
28,298 sh
$94.7K
Filed 03/09
Traded 03/09